AxoGen, Inc. (NASDAQ:AXGN) the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, will report results for the first quarter ended March 31, 2014 on Wednesday, April 30, 2014 after the market closes. AxoGen, Inc. (NASDAQ:AXGN) shares after opening at $2.87 moved to $2.87 on last trade day and at the end of the day closed at $2.80. Company price to sales ratio in past twelve months was calculated as 4.48 and price to cash ratio as 2.43. AxoGen, Inc. (NASDAQ:AXGN) showed a negative weekly performance of -3.45%.
Investment analysts at Canaccord Genuity started coverage on shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) in a note issued to investors on Wednesday, StockRatingsNetwork.comreports. The firm set a “buy” rating and a $28.00 price target on the stock. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) shares advanced 0.46% in last trading session and ended the day on $8.76. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) return on equity ratio is recorded as 60.90% and its return on assets is -316.70%.
The Compensation Committee of Oragenics, Inc (NYSEMKT:OGEN) approved the 2014 performance objectives for the Company’s President and Chief Executive Officer, Dr. John Bonfiglio under his cash bonus plan. Dr. Bonfiglio’s employment agreement with the Company required the adoption of a bonus plan to provide for an annual bonus target of up to 50% of his annual base salary which currently equates to $147,500 (the “Bonus Target”). Oragenics Inc (NYSEMKT:OGEN) shares moved down -6.33% in last trading session and was closed at $2.22 while trading in range of $2.15 – $2.39 – Oragenics Inc (NYSEMKT:OGEN) year to date (YTD) performance is -21.00%.
Paul M Gilbert, a former director of Derma Sciences, Inc. (NASDAQ:DSCI) resigned from the board of directors of the Company, effective as of March 21, 2014 (the “Effective Date”). The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Derma Sciences Inc (NASDAQ:DSCI) weekly performance is -4.04%. On last trading day company shares ended up $9.73. Derma Sciences Inc (NASDAQ:DSCI) distance from 50-day simple moving average (SMA50) is -23.98%. Analysts mean target price for the company is $19.00.